A phase I clinical trial evaluated the small molecule A2AR antagonist, ciforadenant (previously known as CPI-444), in patients with advanced refractory RCC, showing clinical responses both as monotherapy and in combination with atezolizumab (anti-PD-L1 antibody). The gene discussed is ADORA2A; the disease is renal cell carcinoma.